Neuro-Oncology: The Podcast

108 Folgen

1. Pre-operative [11C]methionine PET for low-grade glioma

   Vom: 16.12.2022
2. The role of T lymphocytes in the glioma pathobiology

   Vom: 2.12.2022
3. CDKN2A homozygous deletion in IDH mutant astrocytoma

   Vom: 8.10.2022
4. EGFR: the lazarus target in glioblastom

   Vom: 23.9.2022
5. Brain metastases; a SNO consensus review: Part 2

   Vom: 9.9.2022
6. Brain metastases; a SNO consensus review: Part 1

   Vom: 26.8.2022
7. Pediatric IDH mutant gliomas

   Vom: 13.8.2022
8. Low-risk meningioma: Outcomes from NRG 0539

   Vom: 29.7.2022
9. Selumetinib in children with NF1 and plexiform neurofibroma

   Vom: 1.7.2022
10. Targeted therapy for BRAF-mutant pediatric glioma

    Vom: 17.6.2022
11. Early/evolving IDH wild-type glioblastoma

    Vom: 20.5.2022
12. PI3K signaling in IDH mutant gliomas

    Vom: 6.5.2022
13. Cell-free DNA from CSF in pediatric, adolescent and young adult patients

    Vom: 22.4.2022
14. Molecular determinants of neurocognitive deficits in glioma

    Vom: 8.4.2022
15. H3K27M cell-free tumor DNA tracking in response to ONC201 treatment for diffuse midline glioma

    Vom: 25.3.2022
16. Clinical trial accrual for women and minorities in neuro-oncology

    Vom: 11.3.2022
17. The clinical utility of next generation sequencing for IDHwt glioblastoma

    Vom: 11.2.2022
18. Trabectedin for recurrent grade 2 or 3 meningiomas

    Vom: 28.1.2022
19. Glioblastoma cell heterogeneity and plasticity

    Vom: 14.1.2022
20. Moleculary integrated grading for meningioma

    Vom: 24.12.2021